A double-blinded extension study to provide adjuvant treatment with single agent Herceptin�® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03
A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin�® in subjects with HER2 positive early breast cancer
100 Clinical Results associated with Tanvex Biologics, Inc.
0 Patents (Medical) associated with Tanvex Biologics, Inc.
100 Deals associated with Tanvex Biologics, Inc.
100 Translational Medicine associated with Tanvex Biologics, Inc.